Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan ZIIHERA Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    ZIIHERA (zanidatamab-hrii) IV Therapy Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Part B coverage and prior authorization for intravenous ZIIHERA in adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. It specifies the covered indication, dosing regimen, treatment duration, infusion timing, and billing identifiers.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyZIIHERA (zanidatamab-hrii) IV Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming HER2 IHC 3+ status, qualifying disease extent, prior systemic treatment failure, baseline LVEF of at least 50%, single-agent use, and the requested dose and schedule.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    HER2 IHC 3+ BTCCovered disease and biomarker
    20 mg/kgRecommended IV dose
    Every 2 weeksDosing frequency
    LVEF ≥ 50%Baseline cardiac function
    6 monthsInitial coverage duration
    12 monthsReauthorization duration

    Coverage Criteria

    FDA-Approved Indication

    Covered when ALL of the following FDA-approved indication criteria are met:

    ALL of the following

    • Patient is an adult.
    • Patient has previously treated biliary tract cancer (BTC), including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer.
    • Disease is unresectable or metastatic.
    • Disease is HER2-positive (IHC 3+), as detected by an FDA-approved test.

    Dosing and Administration

    ZIIHERA is authorized for the following regimen and administration requirements:

    ALL of the following

    • Biliary tract cancer regimen: 20 mg/kg by intravenous infusion every two weeks.20 mg/kg every 2 weeks
    • Maximum dose is 20 mg/kg per dose.20 mg/kg/dose
    • Continue treatment until disease progression or unacceptable toxicity.

    Coverage is excluded for patients with untreated or symptomatic central nervous system (CNS) metastases.

    ZIIHERA must be administered by a physician as an intravenous infusion in an office or hospital outpatient department (HOPD). Self-administration is not covered.

    Initial Therapy

    Initial coverage is available when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of biliary tract cancer.
    • Prescribed by or in consultation with an oncologist.
    • Patient is at least 18 years old.>= 18 years
    • Disease is HER2-positive (IHC 3+) as determined by an FDA-approved test.
    • Disease is unresectable, resected gross residual (R2), or metastatic.

    Continuation and Reauthorization

    Continuation and reauthorization are subject to the following requirements:

    ALL of the following

    • Initial coverage is approved for six months.6 months
    • Reauthorization is approved for 12 months.12 months
    • Dose remains consistent with FDA-approved labeling or accepted standards of medical practice.

    Billing and Coding

    10-digit NDCNDC
    68727-950-01Vial
    68727-950-02Carton
    11-digit NDCNDC
    68727-0950-01Vial
    68727-0950-02Carton
    HCPCS CodeHCPCSCovered
    J9276Injection, zanidatamab-hrii, 2 mg
    10-digit NDCNDC
    68727-950-01Vial
    68727-950-02Carton
    11-digit NDCNDC
    68727-0950-01Vial
    68727-0950-02Carton
    HCPCS CodeHCPCS
    J9276Injection, zanidatamab-hrii, 2 mg
    CPT Procedural CodesCPT
    96413Chemotherapy IV infusion, up to one hour
    96415Chemotherapy IV infusion, additional hour*
    HCPCS Drug CodeHCPCS
    J9276Injection, zanidatamab-hrii, 2 mg
    CPT Procedural CodesCPT
    96413Chemotherapy IV infusion, up to one hour
    96415Chemotherapy IV infusion, additional hour
    HER2 expression
    HER2 expressionIHC 3+
    Detection methodFDA-approved test
    Covered disease contextHER2-positive biliary tract cancer
    Maximum dose
    Maximum dose20 mg/kg/dose
    Administration

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required

    Submit a prior authorization request for ZIIHERA to support treatment within the FDA-approved indication for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer.

    Documentation Required

    Document Biliary Tract Cancer Criteria

    Document biliary tract cancer and confirm that the request meets the applicable approval criteria, including adult age, HER2-positive disease, qualifying disease status, and prior treatment.

    • Diagnosis of biliary tract cancer
    • Patient is at least 18 years old
    • Disease is unresectable, resected gross residual (R2), or metastatic

    Background

    ZIIHERA (zanidatamab-hrii) is a bispecific HER2-directed antibody administered by intravenous infusion. Coverage is for adults 18 years or older with previously treated, unresectable, resected gross residual (R2), or metastatic HER2-positive biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer. HER2-positive disease must be confirmed as IHC 3+ by an FDA-approved test.

    Definitions

    Biliary tract cancer
    Intrahepatic siteIntrahepatic cholangiocarcinoma
    Extrahepatic siteExtrahepatic cholangiocarcinoma
    Additional siteGallbladder cancer
    HER2-positive (IHC 3+)
    HER2-positive definitionImmunohistochemistry (IHC) 3+ status
    Required testFDA-approved test
    Disease applicationBiliary tract cancer

    Initial Therapy Criteria

    Initial Therapy — FDA-Approved Indication and Regimen

    Initial treatment is covered when all of the following are met:

    FDA-approved indication and regimen

    • The patient is an adult with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer, confirmed by an FDA-approved test.HER2 IHC 3+
    • ZIIHERA is administered by intravenous infusion at 20 mg/kg every two weeks.20 mg/kg IV every two weeks

      The maximum dose is 20 mg/kg per dose.

    Initial Therapy Eligibility — Biliary Tract Cancer

    Initial therapy requires all of the following criteria and at least one dosing or evidence pathway:

    Continuation and Reauthorization Criteria

    Continuation Therapy

    Continue treatment when clinically appropriate:

    Continuation of therapy

    • Continue ZIIHERA until disease progression or unacceptable toxicity.Until disease progression or unacceptable toxicity

    Reauthorization

    Initial coverage is six months; reauthorization is 12 months. Dosing is approved according to FDA-approved labeling or within accepted standards of medical practice:

    • Initial coverage is authorized for six months.6 months

    Step Therapy

    StepRequirementExamples of qualifying prior systemic therapy
    1Patient must have failed at least one prior systemic treatment for biliary tract cancer before ZIIHERA approval.5-FU; capecitabine; capecitabine plus oxaliplatin; FOLFOX; gemcitabine; gemcitabine plus Abraxane; gemcitabine plus cisplatin; gemcitabine plus Imfinzi and cisplatin; gemcitabine plus Keytruda and cisplatin; or gemcitabine plus oxaliplatin.

    Quantity Limits and Product Configuration

    Quantity limit
    DrugZIIHERA (zanidatamab-hrii)
    Dose per administration20 mg/kg per dose
    Route and frequencyIV infusion every two weeks
    Product availability
    Product formSingle-dose vial containing lyophilized powder
    Strength300 mg per vial
    Carton contentsTwo 300 mg single-dose vials per carton

    Site of Care

    Billing Rule

    Office administration required

    Administer ZIIHERA as a physician-administered IV infusion in the office. Self-administration is not allowed.

    Billing Rule

    Hospital outpatient administration

    ZIIHERA may be administered as a physician-administered IV infusion in a hospital outpatient department. Self-administration is not allowed.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyZIIHERA (zanidatamab-hrii) IV Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming HER2 IHC 3+ status, qualifying disease extent, prior systemic treatment failure, baseline LVEF of at least 50%, single-agent use, and the requested dose and schedule.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingProvider Actions and AuthorizationBackgroundDefinitionsInitial Therapy CriteriaContinuation and Reauthorization CriteriaStep TherapyQuantity Limits and Product ConfigurationSite of Care
    Patient has failed at least one prior systemic treatment for biliary tract cancer.
  1. Left ventricular ejection fraction (LVEF) is at least 50% before starting therapy.LVEF >= 50%
  2. ZIIHERA is prescribed as a single agent.
  3. ONE of the following

    • Requested dose does not exceed 20 mg/kg every two weeks.<= 20 mg/kg every 2 weeks
    • Requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use; the prescriber must submit supporting evidence.
  4. IV infusion
    IndicationBiliary tract cancer
    Infusion timing
    Add-on codeCPT 96415
    Additional infusion timeMore than 30 minutes beyond the initial one hour
    Initial infusion codeCPT 96413 covers chemotherapy IV infusion up to one hour
    Maximum dose criterion
    Maximum dose criterionDoes not exceed 20 mg/kg every two weeks
    Standard dosing frequencyEvery two weeks
    Alternative pathwayA dose supported by practice guidelines or peer-reviewed literature may qualify for relevant off-label use when evidence is submitted
    Baseline cardiac function
    Baseline LVEFAt least 50%
    TimingPrior to start of therapy
    Eligibility requirementRequired before ZIIHERA therapy initiation
    Age requirement
    Minimum age18 years
    Eligible populationAdults
    Policy wordingAdults 18 years old or older
    HER2 testing
    HER2 statusHER2-positive
    Test resultIHC 3+
    Testing methodFDA-approved test
    Prior Authorization

    Prior Treatment Failure Required

    Document failure of at least one prior systemic treatment for biliary tract cancer before requesting ZIIHERA.

    • Include the prior regimen, treatment dates when available, and the reason for failure or discontinuation
    Documentation Required

    Covered Indication and HER2 Testing

    Confirm the covered indication and submit HER2 testing documentation. ZIIHERA is covered for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, when HER2 positivity is IHC 3+ by an FDA-approved test.

    • Attach the HER2 test result and identify the FDA-approved test used
    Documentation Required

    Submit Clinical Eligibility Documentation

    Include clinical eligibility documentation with the authorization request so the plan can verify disease status and treatment appropriateness.

    • Diagnosis and biliary tract cancer subtype
    • HER2-positive status (IHC 3+) and FDA-approved test result
    • Unresectable, R2 residual, or metastatic disease status
    • Patient age of at least 18 years
    • No untreated or symptomatic CNS metastases
    • LVEF of at least 50% before starting therapy
    • Prescriber is an oncologist or has oncology consultation
    • ZIIHERA will be prescribed as a single agent
    Documentation Required

    Supporting Evidence for Off-Label Use

    For a nonstandard or off-label request, submit supporting practice guidelines or peer-reviewed literature demonstrating that the proposed use is an accepted standard of medical practice.

    • Prescriber must provide the supporting evidence with the request
    Documentation Required

    Document Prior Systemic Therapies

    Provide a complete history of qualifying prior systemic therapies for biliary tract cancer and identify the treatment that failed.

    • Examples include 5-FU, capecitabine, capecitabine plus oxaliplatin, FOLFOX, gemcitabine, gemcitabine plus nab-paclitaxel (Abraxane), gemcitabine plus cisplatin, gemcitabine plus durvalumab (Imfinzi) plus cisplatin, gemcitabine plus pembrolizumab (Keytruda) plus cisplatin, and gemcitabine plus oxaliplatin
    Denial Risk

    Coverage Denial Conditions

    Coverage may be denied when the request does not satisfy the clinical eligibility criteria or lacks required documentation.

    • No qualifying biliary tract cancer diagnosis
    • Patient is younger than 18 years
    • HER2 status is not IHC 3+ by an FDA-approved test
    • Disease is not unresectable, R2 residual, or metastatic
    • Untreated or symptomatic CNS metastases are present
    • No failed prior systemic treatment is documented
    • Pretreatment LVEF is below 50%
    • Therapy is not prescribed as a single agent
    Denial Risk

    Dose and Off-Label Use Review

    Use the FDA-labeled dose unless the requested dose is supported by accepted standards of medical practice. A dose exceeding 20 mg/kg every two weeks requires supporting practice guidelines or peer-reviewed literature for the relevant off-label use.

    • Document the requested dose and schedule
    • Submit supporting evidence when the request is outside the criterion
    Billing Rule

    Qualifying Administration Setting

    Arrange administration as a physician-directed intravenous infusion in an office or hospital outpatient department. ZIIHERA cannot be self-administered.

    • Physician-administered IV infusion required
    • In-office or HOPD setting
    HER2-positive
    BiomarkerHuman epidermal growth factor receptor 2 (HER2) overexpression
    ScoringIHC 3+
    Testing methodFDA-approved test
    Qualifying disease extent
    UnresectableDisease that cannot be surgically removed
    Resected gross residualGross residual disease classified as R2 after resection
    MetastaticDisease that has spread to distant sites

    Biliary tract cancer eligibility

    • ZIIHERA is administered as a physician-directed intravenous infusion in an office or hospital outpatient department; self-administration is not permitted.
    • The patient has biliary tract cancer.
    • ZIIHERA is prescribed by or in consultation with an oncologist.
    • The patient is 18 years of age or older.≥ 18 years
    • The disease is HER2-positive, determined as IHC 3+ by an FDA-approved test.IHC 3+
    • The disease is unresectable, resected gross residual (R2), or metastatic.
    • The patient does not have untreated or symptomatic central nervous system metastases.
    • The patient has failed at least one prior systemic treatment for biliary tract cancer.At least 1 prior systemic treatment
    • Left ventricular ejection fraction is at least 50% before therapy initiation.≥ 50%
    • ZIIHERA is prescribed as a single agent.Single agent
    • Dose or supporting evidence

      • Standard dose criterion

        • The dose does not exceed 20 mg/kg every two weeks.≤ 20 mg/kg every 2 weeks
      • Supported off-label use

        • The dose or use is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

          The prescriber must submit supporting evidence.

    Reauthorization coverage is authorized for 12 months.12 months
  5. Dosing is consistent with FDA-approved labeling or accepted standards of medical practice.